Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center, speaks on the symptom burden and current therapeutic interventions available for Fabry disease.
There are several current options available for the treatment of Fabry disease, such as enzyme replacement therapy and pharmacological chaperones for some patients, but there remain no medications that can reverse the damage caused by the condition, said Robert J. Hopkin, MD, clinical geneticist, Cincinnati Children's Hospital Medical Center.
Transcript
Can you discuss the current standard of care in Fabry disease?
Once somebody has a diagnosis of Fabry disease, there are a couple of current options. One of them is enzyme replacement therapy and that is typically given by IV [intravenous] infusion every 2 weeks.
There are 2 dosing regimens that are used in the United States, it's usually 1 milligram per kilogram in Europe and in several other parts of the world, there is one company that recommends 0.2 milligrams per kilogram every 2 weeks, and another company that recommends 1 milligram per kilogram.
That's really just replacing the enzyme that is missing and it is given by IV, taken up by the cells, and gets into most parts of the body. A lot of the enzyme is taken up in the kidneys and the heart, which are the main target organs that have life threatening complications associated with them. The enzyme is also distributed to other body parts.
Unfortunately, enzymes are large proteins, and they don't really get into the nervous system very well. So, some of the aspects of Fabry disease are not very well treated with that. In addition, some of the damage done by the time we're starting treatment is irreversible. So, there are some aspects of the disease that need to be treated with symptom-specific treatments.
For example, if somebody has proteinuria, we need to treat the storage disease and the proteinuria. And the proteinuria would be treated with separate kinds of medications. So, a lot of symptoms that go along with Fabry disease. The initial symptoms are often neuropathic pain, GI [gastrointestinal] symptoms, including abdominal pain, recurrent diarrhea, and sometimes nausea and vomiting.
Then, as the disease progresses, you'll see proteinuria with progressive renal damage, eventually leading to end stage kidney disease. And progressive heart disease that can start with bradycardia and then hypertrophic cardiomyopathy, sometimes rhythm disturbances, and eventually life threatening heart problems like heart failure or heart rhythm disturbances. So, we need to treat all of those things.
Now, in addition to the enzyme replacement therapy, for people who have the right mutations, there is an oral medication that functions as a chaperone. So, if your body makes some of the protein, then the chaperone molecule makes or helps to get the folding pattern of the protein into a physiologic form and maintains the stability so that the enzyme can be transported to the lysosome and function.
People who have mutations that are responsive to that can take an oral medication that, once taken every other day, basically optimizes your body's ability to make the enzyme. Both of those treatment options have been shown to be useful, and they do clearly benefit the patients, but they don't reverse damage that's already been done. And they don't directly impact all of the manifestations of Fabry disease as completely as we would like.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More